Discussion: What information should we be collecting from clinical trials to better inform drug development in this space?

Group discussion session at Genetics-inspired Therapeutics for PH

Summary

This video explores crucial aspects of improving drug development for Pulmonary Hypertension (PH). It highlights the necessity of collecting validated, objective data, including Patient-Reported Outcomes, to support new therapeutic advancements. The discussion emphasizes strategic planning, regulatory collaboration, and the evolution of clinical trial design to better reflect patient benefit and real-world outcomes.

Generated by AI, edited by PVRI